Home › NDC Lookup › Ingredients › Lidocaine - 4% › 83720-0523-01
Lidocaine 4% Topical Anesthetic Cream 4 g/100g Cream — NDC 83720-0523-01 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Lidocaine 4% Topical Anesthetic Cream 4 g/100g Cream — NDC 83720-523-01 (Billing 83720-0523-01)

by Oncor Pharmaceuticals · 1 TUBE in 1 CARTON / 30 g in 1 TUBE

This is a package of Lidocaine 4% Topical Anesthetic Cream 4 g/100g Cream from Oncor Pharmaceuticals, marketed since May 2024 and currently FDA-listed; retail pharmacies pay about $0.4899 per g (NADAC). It is this product's only package size.

NDC 83720-0523-01
🏷️ FDA NDC (as labeled) 83720-523-01 billing pads the product segment with a zero
OTC On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 83720-523-01
Product NDC 83720-523
11-digit billing NDC 83720052301
NCPDP billing unit GM — per gram (weight)
RxCUI 1421893
UNII 98PI200987
Application # M017
SPL Set ID 1baaa669-05af-4024-a0ba-ee3451756f6a
Established class (EPC) Amide Local Anesthetic; Antiarrhythmic
Physiologic effect Local Anesthesia
Chemical class Amides
DEA schedule Non-controlled
Marketing category OTC MONOGRAPH DRUG
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2024-05-22
Route TOPICAL
Dosage form CREAM
Substance LIDOCAINE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 90850060003720
GCN Seq No 040262
GCN 95405
HICL code 010705
Ingredient (HICL) Lidocaine
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5H
Therapeutic class — specific (HIC3) Topical Local Anesthetics
AHFS code 72:00.00.00
AHFS class Local Anesthetics
FDB label name LIDOCAINE 4% CREAM
FDB brand name Lidocaine
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 040262
  • GCN: 95405
  • GPI-14 (Medi-Span): 90850060003720
  • HICL (First Databank): 010705
  • AHFS class code: 72:00.00.00
  • RxCUI (RxNorm): 1421893
Why two NDCs? The FDA registers this code as 83720-523-01 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 83720-0523-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Antiarrhythmic class.

Pharmacologic class Antiarrhythmic, Amide Local Anesthetic
Drug family (ATC) Antiarrhythmics, class Ib, Local anesthetics, Anesthetics for topical use
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name LIDOCAINE 4% CREAM Ingredient Lidocaine
📗 Our plain-language guide HelloPharmacist
  • Lidocaine numbs the area where it is used. Clinicians inject it for procedures. Skin products are used for pain, itching, minor burns, insect bites, hemorrhoid discomfort, and in s...
  • Clean and dry the skin first, then apply as your product’s directions say. Wash your hands afterward. Don’t exceed the number of uses on the label. Ask a doctor before using a prod...
  • No. Heat can increase how much lidocaine your body absorbs. Don’t bandage tightly either. Also avoid using other topical pain products at the same time.
  • Can I use a heating pad with a lidocaine patch?
📖 Read our full Lidocaine guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.490 $14.70 / 30 g
Medicaid paysCMS SDUD · 12 mo $0.5657 $16.97 / 30 g
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per g) — tap or hover for the price & month
Dec 2025 Mar 2026 Jun 2026 Sep 2026 $0.540 $0.475
Flat over the last 10 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
83720-0523-01 You're viewing this Main listing 1 TUBE in 1 CARTON / 30 g in 1 TUBE 2024-05-22 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Rugby Lidocaine 4 g/100g 00536-1357-95 Rugby 1 tube $0.428 — Availability likely save 13%
Lidocaine 4% Topical Anesthetic Cream 4 g/100gthis 83720-0523-01 Oncor 1 tube $0.490 — Availability likely —
4 Lidocaine Topical Anesthetic 40 mg/g 00536-1267-20 RUGBY 15 g $0.635 — Availability likely +30%
Lidocaine 40 mg/g 39328-0024-15 Patrin 1 tube $0.635 — Availability likely +30%
Numbing Pain Relief 4 g/100g 00363-6261-07 Walgreen 1 applicator — — FDA listed —
Lmx4 40 mg/g 00496-0882-05 Ferndale 5 g — — FDA listed —
Lidocaine 40 mg/g 10135-0672-96 Marlex 1 tube — — FDA listed —
Anecream 4 g/100g 24357-0701-06 Focus 5 tubes — — FDA listed —
Meijer Analgesic Lidocaine Topical Analgesic 40 mg/g 41250-0518-01 Meijer 1 bottle — — FDA listed —
Lidocaine 4 g/100g 42291-0399-30 AvKARE 1 tube — — FDA listed —
Pain free IV 4 g/100mL 54723-0008-01 Sambria 4 ml — — FDA listed —
Painless Tattoo 2 4 g/100mL 54723-0016-01 Sambria 4 ml — — FDA listed —
NeuroMed Topical Anesthetic 7 40 mg/g 54723-0300-04 Sambria 4 g — — FDA listed —
Family Wellness Pain Relief with Lidocaine 40 mg/g 55319-0822-50 FAMILY 1 tube — — FDA listed —
Lidocaine 40 mg/g 58980-0824-05 Stratus 1 tube — — FDA listed —
Burn Relief Professional Bio-Kool 4 g/100g 61566-0201-04 Kool-Down 113 g — — FDA listed —
Desert Harvest RELEVEUM 40 mg/mL 69145-0201-04 Desert 118 ml — — FDA listed —
Lidocaine Anesthetic Cream 4 g/100g 69375-0005-30 Nationwide 1 tube — — FDA listed —
Tylenol Precise Warming Pain Relieving 40 mg/g 69968-0794-04 Kenvue 1 tube — — FDA listed —
Tylenol Precise Pain Relieving 40 mg/g 69968-0795-04 Kenvue 1 tube — — FDA listed —
Blue-Emu Lidocaine Pain Relief Cream 40 mg 69993-0350-03 Kingsway 1 tube — — FDA listed —
Lidocaine Cream, 4% 4 g/100g 71085-0075-19 IPG 119 g — — FDA listed —
Deeveeant Numb 40 mg/g 71383-0014-02 Valekista 1 tube — — FDA listed —
MediNumb 40 mg/g 71383-0024-02 Valekista 1 tube — — FDA listed —
Asper Flex 4 g/100g 71399-0049-01 Akron 15 g — — FDA listed —
Lidocaine 4% 4 g/100g 71800-0026-06 Innovida 58.5 g — — FDA listed —
Lidozall 4 g/100g 72835-0004-20 V2 20 packets — — FDA listed —
Lidocaine 4% Topical Anesthetic Cream 4.27 g/100g 73715-0001-01 Mohnark 30 g — — Discontinued —
Meijer Pain Relief Cream 4 g/100g 79481-0048-02 Meijer 76.5 g — — FDA listed —
Lidocaine 40 mg/g 80425-0351-01 Advanced 1 tube — — FDA listed —
Lidocaine 4% Cream 40 mg/g 82461-0419-30 Medcore 1 tube — — FDA listed —
AUVON Pain Relief Cream 4 g/100g 83391-0009-01 SHENZHEN 57 g — — FDA listed —
RelaxInk LIDOCAINE 4 g/100g 83714-0004-01 Hambli 1 tube — — FDA listed —
ELAIMEI Numbing Cream 4 g/100mL 83804-0005-01 Shenzhen 1 bottle — — FDA listed —
Tktalker Numbing 4 g/100g 83804-0113-01 Shenzhen 50 g — — FDA listed —
Dcsily Numbing Cream 4 g/100g 83818-0034-01 Shenzhen 50 g — — FDA listed —
4% TATTOO Numb Cream 100 mg/g 84019-0030-01 Shengnan 30 g — — FDA listed —
Signature Pain Relief Cream 40 mg/g 84019-0044-01 Shengnan 30 g — — FDA listed —
Nekvnro LIDOCAINE 4% Tattoo numbing cream set 4 g/100g 84844-0018-01 Guoyu 2 tubes — — Discontinued —
VBBV Tattoo Numbing 40 mg/mL 84867-0014-01 Jiashen 60 ml — — FDA listed —
Black Cobra Tattoo Numbing Cream 4% Lidocaine .04 g/g 84938-0002-01 Foshan 20 g — — FDA listed —
Jakwork Numbing Cream 4 g/100g 85150-0007-01 Guangzhou 50 g — — FDA listed —
Healmusz Numbing 4 g/100g 85248-0032-01 Jiangxi 50 g — — FDA listed —
Nieapf NUMBING 4 g/100g 85248-0046-01 Jiangxi 65 g — — FDA listed —
Subleef NUMBING 4 g/100g 85248-0052-01 Jiangxi 30 g — — FDA listed —
Sylvirene Numbing 4 g/100g 85248-0070-01 Jiangxi 50 g — — FDA listed —
ANIXIKE Numbing 4 g/100g 85248-0088-01 Jiangxi 30 g — — FDA listed —
Dermfree Numbing 4 g/100g 85248-0121-01 Jiangxi 50 g — — FDA listed —
ANIXIKE Numbing 4 g/100g 85248-0166-01 Jiangxi 30 g — — FDA listed —
YYSDMVY NUMBING Cream 4 g/100g 85248-0209-01 Jiangxi 60 g — — FDA listed —
Tattoo numbing cream 4 g/100g 85284-0001-01 BLOOMWELL 50 g — — FDA listed —
Topical Cream 4 g/100g 85284-0002-01 BLOOMWELL 50 g — — Discontinued —
Numbing Cream 4 g/100g 85284-0003-01 BLOOMWELL 50 g — — Discontinued —
numbing cream MAXIMUM STRENGTH 4 g/100g 85284-0006-01 BLOOMWELL 50 g — — Discontinued —
Veiurkiu External Analgesic Cream 4 g/100g 85284-0011-01 BLOOMWELL 50 g — — FDA listed —
Numbing Cream 40 mg/g 85569-0001-01 100 50 g — — FDA listed —
Numbing Cream 4 mg/100mL 85569-0002-01 100 50 ml — — FDA listed —
SCHOELIF Numbing Cream 4 g/100g 85817-0001-01 Guangzhou 50 g — — FDA listed —
Aouiv 4% Lidocaine Numbing Cream 4 g/100g 85817-0003-01 Guangzhou 60 g — — FDA listed —
Numbing Creams 4 g/100g 85881-0001-01 Yongchun 50 g — — FDA listed —
Black Cobra 4% Lidocaine Numbing Cream 40 mg/g 85924-0001-02 BLACKCOBRASUPPLY, 1 tube — — Discontinued —
Swiftalyn Numbing Cream 4 g/100g 87013-0002-01 GENUINE 50 g — — FDA listed —
Morovan 4 g/100g 87800-2624-01 HONG 1 can — — FDA listed —
Hempvana Ultra Strength Pain Relief Cream 4 g/100g 73287-0016-01 Telebrands 1 jar — — FDA listed —
Numbsure LIDOCAINE 4 g/100g 83714-0003-01 Hambli 1 tube — — FDA listed —
Hempvana Ultra Strength Pain Relief Cream Platinum 4% Lidocaine 4 g/100g 73287-0042-01 Telebrands 1 jar — — FDA listed —
Lubricaine 4 g/100g 63135-0727-04 ESBA 113 g — — FDA listed —
Topicaine 4 g/100g 63135-0312-04 ESBA 113 g — — Discontinued —
Recovery Numb 4 g/100g 49436-0099-30 PURKLENZ 30 g — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2024
On the market since
May 2024
📍
2026
Currently FDA-listed
2 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 936JST6JCN
    Cetyl alcohol is a waxy, fatty substance derived from plant or animal sources. It acts as an emulsifier and thickener in medicines, helping blend oil and water components and giving products a smooth, creamy texture.
  • UNII DSO12WL7AU
    A salt derived from citric acid, this ingredient acts as a buffer and pH regulator in medicines. It helps maintain stable acidity levels and may improve taste or aid preservation.
  • UNII PDC6A3C0OX
    Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
  • UNII FCZ5MH785I
    A waxy substance made from glycerin and stearic acid. It works as an emulsifier to help mix oil and water ingredients together, and as a thickener to give the medicine its proper texture and consistency.
  • UNII T5L8T28FGP
    Mineral oil is a clear, odorless liquid derived from crude oil. It acts as a lubricant and emollient in medications, helping pills slide smoothly during manufacturing and aiding moisture retention in topical products.
  • UNII YD01N1999R
    A waxy substance made from polyethylene glycol and stearic acid. It helps mix oil and water-based ingredients together and serves as an emulsifier and solubilizer in liquid and semi-solid medicines.
  • UNII HIE492ZZ3T
    Phenoxyethanol is a synthetic preservative and antimicrobial agent used to prevent bacterial and fungal growth in medicines and cosmetic products, extending shelf life and maintaining product safety.
  • UNII 2KR89I4H1Y
    Stearyl alcohol is a waxy, fatty substance derived from natural oils or made synthetically. It acts as an emulsifier and thickener in medicines, helping mix ingredients together and give the product the right texture.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
  • UNII B6E5W8RQJ4
    White petrolatum is a purified mineral oil product used as a lubricant and skin protectant in medications. It helps pills slide through manufacturing equipment and can soften or protect the skin when applied topically.
  • UNII TTV12P4NEE
    Xanthan gum is a thickening and stabilizing ingredient made from fermented corn or other sugars. It's added to medicines to improve texture, prevent separation of liquids and solids, and help the product stay consistent.

11 inactive ingredients listed in the exact product block matched to this NDC.

The official label also statesCetyl alcohol, Citric acid, Glycerin, Glyceryl stearate SE, Mineral oil, PEG-100 stearate, Phenoxyethanol, Purified water, Stearyl alcohol, White petrolatum, Xanthan gum.

Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerOncor Pharmaceuticals
FDA applicationM017 (OTC MONOGRAPH DRUG)
Labeler code83720
First marketedMay 2024
Product typeHuman Otc Drug
Portfolio9 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 📦 Storage and Handling 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose 📄 Ask a Doctor Before Use If 📄 When Using This Product 📄 Keep Out of Reach of Children 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 20 words ▾

Uses Temporarily relieves pain and itching due to: Minor cuts Minor scrapes Sunburn Minor burns Minor skin irritations Insect bites

⏱️ Dosage and Administration 28 words ▾

Directions Adults and children 2 years and older: apply externally to the affected area up to 3-4 times daily. Children under 2 years of age: consult a physician.

⚠️ Warnings 5 words ▾

Warnings For external use only.

📦 Storage and Handling 26 words ▾

Other information Store at USP controlled room temperature 20°-25°C (68°-77°F). Manufactured In USA For : ONCOR PHARMACEUTICALS 8815 Center Park Dr Suite 430 Columbia Maryland 21045

🧪 Active Ingredient 7 words ▾

Drug Facts Active Ingredients Lidocaine 4% w/w

🧪 Inactive Ingredients 23 words ▾

Inactive Ingredients Cetyl alcohol, Citric acid, Glycerin, Glyceryl stearate SE, Mineral oil, PEG-100 stearate, Phenoxyethanol, Purified water, Stearyl alcohol, White petrolatum, Xanthan gum.

🎯 Purpose 3 words ▾

Purpose Topical Anesthetic

📄 Ask a Doctor Before Use If 38 words ▾

Stop use and ask a doctor if Allergic reaction occurs. Condition worsens or does not improve within 7 days. Symptoms clear up and return within a few days. Redness, irritation, swelling, pain or other symptoms begin or increase.

📄 When Using This Product 25 words ▾

When using this product Do not use in or near the eyes. Do not use in large quantities, particularly over raw surfaces or blistered areas.

📄 Keep Out of Reach of Children 40 words ▾

Keep out of reach of children If swallowed, get medical help or contact a Poison Control Center right away. You may report side effects by calling Oncor Pharmaceuticals (9 a.m. to 5 p.m. EST), at 1-443-876-7900 or FDA at 1-800-FDA-1088.

📄 Package Label / Principal Display Panel 49 words ▾

Package Label ONCOR PHARMACEUTICALS NDC 83720- 523 -01 Lidocaine 4% Cream Topical Anesthetic Cream For External Use Only Not For Ophthalmic Use This product contains child-resistant packaging. To open, push down on the cap of the tube while turning and lift off. NET WT.

1.05OZ. (30 gm) Carton

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
1.4K
Units reimbursed last 4 qtrs
58K
Gross reimbursed last 4 qtrs
$32.8K
Avg / prescription
$24.20
Avg / unit
$0.5657
Latest quarter Q1 2026
357Rx
Medicaid pays / g
$0.5657
gross reimbursed
vs
NADAC / g
$0.4899
acquisition cost
=
Spread
+$0.0758
+15% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
75% FFS 25% MCO
Fee-for-service · 1,023 Rx Managed care · 333 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: 22,410 units · 223 per 100k residents MI New York: 18,245 units · 93.2 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: 780 units · 6.6 per 100k residents OH Pennsylvania: 3,442 units · 26.6 per 100k residents PA New Jersey: 9,028 units · 97.2 per 100k residents NJ Massachusetts: no data reported MA California: 4,110 units · 10.5 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
6.6223
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Michigan 223 /100k
2 New Jersey 97.2 /100k
3 New York 93.2 /100k
4 Pennsylvania 26.6 /100k
5 California 10.5 /100k
6 Ohio 6.6 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Lidocaine 4% Topical Anesthetic Cream (this brand).

Top reported reactions

Nausea32
Pain25
Headache22
Dizziness18
Vomiting18
Hypotension17
Fatigue14

Age at onset

Infant1
Adult20
Elderly9

Reporter sex

432 reports
Male · 45%
Female · 54%
Unknown · 1%

Serious outcomes

Hospitalization137
Life-threatening53
Death30
Disabling21
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 32 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
← 83720-0503-16 · Oncor 83720-0542-16 · Oncor →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.